Microbial MIA Biosynthesis for Halogenated Alkaloid Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Producing monoterpene indole alkaloids (MIAs) at scale is challenging due to supply chain shortages and poor yields from plant extraction, and chemical synthesis faces difficulties in separating stereoisomers, while microbial cell factories offer a promising solution but face barriers in new-to-nature chemistries with slow-growing plants of limited genetic tractability.
Innovation Solution
A method for producing MIAs and derivatives, including halogenated forms, by expressing a heterologous biosynthesis pathway in microorganisms, utilizing geraniol synthase (GES) and strictosidine-O-β-D-glucosidase (SGD) to convert substrates into strictosidine aglycone and halogenated derivatives, with co-localization of pathway enzymes improving product titers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If plant extraction is used to produce MIAs, then natural source availability is improved, but supply chain reliability and yield are worsened
Solution Approach 1:
The patent uses microbial cell factories as synthetic copies of plant metabolic pathways. Engineered microorganisms (yeast, bacteria) are designed to replicate the complex biosynthesis pathway that naturally occurs in plants, allowing scalable production without relying on plant extraction. This copying approach enables consistent supply while maintaining the ability to produce diverse MIA structures.
Solution Approach 2:
The patent replaces the mechanical extraction process (physically harvesting MIA compounds from plants) with a biological synthesis system. Instead of mechanically extracting compounds from plant tissues, the invention uses engineered microbial cells that metabolically synthesize MIAs through controlled enzymatic pathways, substituting mechanical extraction with biochemical production.
2Productivity
If total chemical synthesis is used to produce MIAs, then production scalability is improved, but manufacturing precision is worsened due to stereoisomer separation difficulties
Solution Approach 1:
The patent employs self-service by utilizing the microbial cell's own metabolic machinery to synthesize MIAs with correct stereochemistry. The engineered microorganisms possess the complete enzymatic pathway that naturally produces MIAs with the correct three-dimensional configuration, eliminating the need for separate stereoisomer separation steps. The system serves its own purpose of producing enantiomerically pure compounds through its engineered metabolism.
Solution Approach 2:
The patent changes the fundamental parameter of production from chemical synthesis to biological synthesis. By transitioning from chemical methods (which produce racemic mixtures requiring separation) to biological methods (which inherently produce single enantiomers through enzymatic catalysis), the invention resolves the stereoisomer separation issue while maintaining scalability.
3Adaptability or versatility
If heterologous enzyme expression is used to introduce unnatural elements, then chemical diversity is improved, but device complexity is worsened due to multiple enzyme modules required
Solution Approach 1:
The patent applies segmentation by dividing the MIA biosynthesis pathway into distinct enzymatic modules that can be independently engineered and expressed in the microorganism. Each module corresponds to a specific transformation step (e.g., halogenation, cyclization, glycosylation), allowing modular assembly of metabolic pathways to produce diverse MIA structures without requiring complete redesign of the entire system.
Solution Approach 2:
The patent achieves universality by creating a flexible metabolic platform where a single microbial host can be engineered to produce multiple different MIA structures by simply changing the substrate or regulating existing enzymes. The core microbial cell serves as a universal factory that can be adapted to synthesize various MIAs, halogenated derivatives, and other natural products through modular enzymatic additions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
De novo production of MIAs and halogenated derivatives is achieved at reduced financial and environmental costs, with improved yields and product titers, using engineered microorganisms like Saccharomyces cerevisiae and Escherichia coli.
Implementation Method 1
The GES is a geraniol synthase capable of converting GPP to geraniol
Implementation Method 2
The SGD is a strictosidine-O-β-D-glucosidase capable of converting strictosidine or halogenated strictosidine to strictosidine aglycone or halogenated strictosidine aglycone
Implementation Method 3
Methods for producing monoterpene indole alkaloids (MIAs) and derivatives thereof de novo in a microorganism
Data Source
AI summary
The present invention relates to microorganisms for producing monoterpene indole al-kaloids (MIAs) and derivatives thereof de novo, including halogenated MIAs and halo-genated derivatives thereof. Also provided herein are methods for producing MIAs and derivatives thereof de novo, in particular halogenated MIAs and derivatives thereof, in a 5 microorganism, as well as useful nucleic acids, vectors and host cells for performing the present methods.